Agoracom Blog Home

Archive for the ‘AGORACOM Client Feature’ Category

CLIENT FEATURE: Draganfly $DFLY.ca $DFLYF A 20+ Year Old Technology Developer Specializing In #Drones, #Sensors and #AI $FLT.ca $UAVS $ALPP

Posted by AGORACOM-JC at 3:48 PM on Wednesday, March 24th, 2021

(DFLY: CSE) (DFLYF: OTCQB) (3U8: FSE)

www.draganfly.com

WHY DRAGANFLY?

  • Considered the oldest commercial drone company in the world (1998)
  • Built the first drone that saved a life
  • Boasts the first drone to be inducted into the Smithsonian National Air & Space Museum
  • More than just drones – A technology developer creating drone based solutions
  • Draganfly Commander Drone selected by US Department of Agriculture
  • Developing vaccine drone delivery payload system
  • $2.9M in revenue for first 9 months of 2020
  • Selected to provide engineering and development services for a drone-based Air Support Defense System for Integrated Launcher Solutions
  • Strategic partnership with Woz ED, Apple Co-Founder Steve Wozniak’s K-12 Education program
  • Entering significant growth phase due to multiple revenue streams
  • Clients include: Global law enforcement and Tier-1 Enterprise companies

Signed $1M services deal to deploy EagleEye ™ AI flight services with Windfall Geotek

The North America Unmanned Aerial Vehicle market was valued at $USD 1.7 billion in 2017 and is likely to exceed $USD 7 billion by 2024 (Global Market Insights)

DraganFly and Windfall Geotek Landmines Solution Is a $700M Annual Market Whose Biggest Payoff Is Lives Saved

FULL DISCLOSURE: Draganfly is an advertising client of AGORA Internet Relations Corp.

CLIENT FEATURE: Novamind $NM.ca Leaders In #Psychedelic Medicine $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 11:44 AM on Friday, February 12th, 2021

NM: CSE

Why Novamind?

  • Building the infrastructure required for a regulated psychedelics industry
  • Rapidly expanding a network of outpatient mental health clinics and research sites
  • Provides ketamine-assisted psychotherapy and Spravato™ (esketamine) treatments;
    • Ketamine treatment volume grew 90% from 2019 to 2020
    • During the same period, total Spravato™ treatments rose 400%
  • Positioned to facilitate MDMA and psilocybin therapy post-FDA approval
  • Specializing in psychedelic-assisted treatment protocols
  • Building centers of excellence for future approved psychedelic treatments
  • Approximately CAN$1,900,000 in 2019 revenue
  • Strong insider ownership (32.3%) 

Yaron Conforti, CEO of Novamind Featured On Cheddar News

Novamind is focused on 3 pillars:

FULL DISCLOSURE: Novamind is an advertising client of AGORA Internet Relations Corp.

Hub On AGORACOM / Corporate Profile

CLIENT FEATURE: The 3 Reasons Why Arctic Star $ADD.ca Is A World Class, Small Cap Diamond Explorer $RIO $DIAM.ca $NAR.ca $MPVD.ca

Posted by AGORACOM-Eric at 10:32 AM on Monday, February 8th, 2021

The 3 Reasons Why Arctic Star Is A World Class, Small Cap Diamond Explorer

Arctic Star Exploration (ADD:TSXV / ASDZF:OTCQB / 82A1.F:FRA) is in the diamond finding business.

The Company owns 100% of its flagship Timantti Diamond Project in Finland, where Arctic Star has discovered three diamondiferous kimberlites that may represent the first finds in a large kimberlite field. If you don’t know what a kimberlite is, keep drilling down and see below because this is truly exciting.

The project is located on the same geological belt as the Grib Diamond Mine in Russia, just 450 kms away. The Grib mine is one of the largest diamond mines in the world and was discovered by a team led by Arctic Star Director Roy Spencer.  Keep drilling down to see more about him.

For those investors who have a little more experience and find themselves asking Why Finland? You should know that Finland was ranked as the World’s #2 mining jurisdiction in the world by the Fraser Institute 2020. In addition to its flagship project in Finland, the Company also controls diamond exploration properties in Nunavut (Stein) and the Northwest Territories of Canada (Diagras and Redemption).

But the real secret of Arctic Star is that it has tremendous potential to revolutionize the way in which Diamonds are discovered – and become a pioneer in the exploration industry – by finding diamonds in a place where no previous explorer has thought to do so. More than just a wild theory, Arctic Star has the team to back it up.

Here are the 3 things you need to know

1. World Class Diamond Finders

Arctic Star exploration has a highly experienced diamond exploration team previously responsible for numerous world class diamond mine discoveries.  The team is led by Buddy Doyle who originally discovered Diavik Mine, Canada’s largest diamond mine in terms of carat production. Diavik’s exceptional grades make it one of the most valuable diamond mines in the world.  Diavik is located in the Northwest Territories of Canada, where Arctic Star has 2 of their diamond properties.

Few geologists have seen 2 projects from discovery through to decision to mine. Mr. Doyle is recognized by his peers in the exploration industry as an authority on diamond exploration and kimberlite geology, and has authored/co-authored numerous papers on these subjects. He was awarded the 2007 Hugo Dummitt Award for excellence in Diamond exploration.

Roy Spencer – If that wasn’t enough, the geologist who discovered the multi-billion-dollar Grib Diamond Mine in Russia (see above). which is just 450 KMs away from Arctic Star’s project in Finland, has now joined Arctic’s Board of Directors!  Clearly, the Arctic Star team has the credibility necessary to put forth a new thesis on how to find diamonds. 

 2. Brand New Exploration Model To Find Diamonds 

In order to find diamonds, you need to first find Kimberlites. What are Kimberlites? Essentially, they are the rocks which contain diamonds. These kimberlite rocks are found underground in vertical structures known as kimberlite pipes. To illustrate in simple terms, see this basic image of a kimberlite pipe with kimberlite rocks inside of it.  

Kimberlite pipes are the biggest source of diamonds today. When exploration companies go looking for kimberlites, the industry standard for finding them is to look for magnetic signatures. This is done by taking a magnetic survey from the air and/or ground. with a device called a magnetometer.  Now, most of you won’t understand what you are looking at – but here is an example of one of the company’s magnetic surveys on its Canadian Diagras property.

The most important thing to understand is that the industry looks for magnetic signatures ….. but Buddy Doyle and the accomplished Arctic Star team have developed a NON MAGNETIC THESIS.  They believe they will find economic diamonds by locating Kimberlite that do not have a magnetic signature where previous explores sought not to look. Arctic in a sense is exploring for diamonds the opposite way the industry traditionally does. Arctic acquired property big mining company’s dropped, because they looked at them one way. Arctic is looking differently and success is occurring quickly for this small, yet accomplished exploration outfit. There are already multiple drill ready targets in 2 countries using this new way of looking for diamonds.

Arctic offers multiple opportunities in 2 countries to turn the Diamond Industry on notice with a discovery.

3. Arctic Star Has Two Diamond Projects Ready To Verify Its Non-Magnetic Theory

Arctic has 2 diamond projects on which to verify its theory: Diagras in Northwest Territories of Canada and Timantti in Finland, where early exploration searching for Non-Magnetic signatures has already yielded multiple new diamond target

A.  Diagras is next to Diavik (Canada’s largest diamond mine) and is drill ready to prove Buddy’s theory. Arctic has plans to drill in 2021

B. Timantti in Finland has 3 separate target areas and 6 targets altogether identified through non-magnetic signatures as a means to find diamonds and further excel Buddy’s theory, it is the company’s goal to drill test in 2021

If Buddy Doyle and the Arctic Star team are correct it will create a new discovery process for understanding how diamonds are brought to surface in areas previous explorers cared not to look. Arctic Star has the potential to create multiple discoveries and copycat companies trying to duplicate their success.

However, there is only one Buddy Doyle and Roy Spencer, which is why Arctic Star is the one Diamond Exploration Company every investor should be aware of.

Click Here To Discover Why Arctic Star Is The Next Diamond Discovery

AGORACOM Small Cap 60: Durango Resources $DGO.ca Drilling The Trove Property in Windfall Lake Adjoining Osisko $OSK.ca $BTR.ca $SII.ca $TLG.ca

Posted by AGORACOM-Eric at 2:45 PM on Thursday, January 14th, 2021

Highlights:

  • Maiden Drill program underway at Trove
  • Located in Windfall Lake gold District
    • Surrounded by Osisko
  • 100% interest in the Trove and East Barry claims
  • Currently the most active gold exploration camp in Canada
    • 21 drill rigs at Windfall in 2020
  • 40% Inside Ownership
    • Marcy Kiesman, President & CEO owns 16%
  • Positioned for Discovery in Windfall Lake

CLIENT FEATURE: Valeo Pharma $VPH.ca $VPHIF An Innovative Canadian Pharma Company With 9 Products Currently Marketed And 7 Products In Pipeline $HLS.ca $MDP.ca $GUD.ca $RX.ca

Posted by AGORACOM-JC at 12:04 PM on Wednesday, January 13th, 2021

(VPH: CSE) (VPHIF: OTCQB) (VP2: FSE)

www.valeopharma.com

Why Valeo Pharma?

  • Commercial stage revenue generating Canadian pharmaceutical company
  • Approaching EBITDA positive in coming months
  • 9 products currently marketed ($40M. estimated peak sales / year)
  • 7 additional products in pipeline ($45M. estimated peak sales / year)
  • In-license business model, no development or clinical risk
  • $1.5M in quarterly revenue ending July 31, 2020
  • $5.26M in revenue for 9 months ending July 31, 2020

What Exactly Does Valeo Pharma Do?

  • Acquires Canadian rights to commercial stage, innovative and proprietary drugs
  • Commercializes innovative prescription products in Canada
  • Focused on Neurodegenerative Diseases,  Oncology and Hospital Specialty Products
  • Internally manages portfolio through all stages of commercialization

Highlights of MDBriefCase Newsletter Comparing Hesperidin and Vitamin C for COVID-19

  • Growing body of research suggests Hesperidin may interfere with SARS-CoV-2 infection process
  • Hesperidin may help against Covid-19 viral replication
  • Hesperidin is a potent antioxidant with anti-inflammatory activity that may help in controlling cytokine storm

Click below to read in its entirety.

Hub On AGORACOM / Corporate Profile

FULL DISCLOSURE: Valeo Pharma is an advertising client of AGORA Internet Relations Corp.

CLIENT FEATURE: Else Nutrition $BABY.ca $BABYF Backed By A $2.7 Billion Global Nutrition Powerhouse $BYND $VERY.ca $INGR $VEGN $TOFB

Posted by AGORACOM-JC at 4:03 PM on Tuesday, January 12th, 2021
http://blog.agoracom.com/wp-content/uploads/2020/03/else-square-150x150.png

Else Nutrition Holdings Inc. (BABY: TSXV) (BABYF: OTCQX) (0YF: FSE) is the award winning, plant-based nutrition company for small cap investors. The shift towards plant-based alternatives has opened the food market to new players, and created an opportunity for fast growth in a rapidly expanding space.  

Highlights include:

  • $CAD 30 Million In Cash
  • Launched 1st Commercial Product Into US Market
  • Backed By A $2.7 Billion Dollar Global Nutrition Company;
  • MOU For International Distribution Of Products
  • “Best Health” Award At Global Food Innovation Summit In Milan;
  • Awarded Patents In 22 Countries, 44 Countries Pending;
  • Executives & Advisors From Globally Renowned Companies & Institutions
  • Distribution agreement with one of the largest and most well regarded national fresh, organic and specialty food distributors in North America
  • Received key Clean Label Certifications for Toddler Nutrition Product
  • Received Key USDA Organic Certification

Else Expands North American Retail Presence as first Baby Category Product on Plant X – a Leading Plant-Based Ecommerce and Digital Community

Hub On AGORACOM / Corporate Profile

Else Nutrition Holdings is an advertising client of AGORA Internet Relations Corp.

CLIENT FEATURE: Xphyto Therapeutics $XPHY.ca Providing Investor Access to Leading Edge Bioscience Opportunities $NGM.ca $SONA.ca $HBP.ca $MIR.ca $IPA.ca

Posted by AGORACOM-Eric at 12:37 PM on Thursday, January 7th, 2021

(CSE:XPHY / OTC:XPHYF / FSE:4XT)

  • Completed Successful SARS-CoV-2 RT-PCR Diagnostic Test Kit Validation
  • Secured Exclusive Psychedelic Drug Development Agreement
  • Appointed European Healthcare Executive to Board of Director
  • Engaged German Partner for Development of Psilocybin API Production
  • Announced Update on Contract Drug Delivery Program
  • Announced Update on Oral Thin Film Drug Delivery Program
  • Provided Update on Parkinson’s Transdermal Patch

Three Xphyto Divisions:

1. Vektor Pharma TF: World-class thin film drug delivery platforms for transdermal and oral dissolvable dosage forms

2. 3a-Diagnostics: Rapid, low-cost screening tests for pandemic and dental health applications

3. Xphyto Laboratories Inc.: Development of industrial production processes for emerging active pharmaceutical ingredients, including psychedelics and cannabinoid isolates

1. Vektor Pharma TF GmbH – Drug Delivery

100% owned XPhyto subsidiary

Global leader in design, testing and manufacture of therapeutic film drug delivery systems

  • Major pharma clients – past, present and future
  • Focused and nimble team – rapid turnaround on new opportunities

Versatile platform technology

  • Transdermal patches (TDS) – slow and steady release
  • Oral dissolvable film (ODF) sublingual strips – instant bioavailability

EU GMP facilities in Baden-Württemberg, Germany

Holder of numerous German narcotics import and manufacturing licences

XPhyto Drug Development Pipeline – Stage 1 & 2

  • Platform technology
  • Scalable product development pipeline
  • High-growth and new API opportunities
  • Neurological indications
  • Generic and hybrid-generic drug formulations

2. 3a-Diagnostics GmbH – Rapid Testing

XPhyto has an exclusive development, technology purchase and licence agreement

Specializing in the development, production, and marketing of low-cost point-of-care screening test systems:

  • COVID-19 rapid PCR Kit
  • COVID-19 disposable ultra-rapid test
  • Oral biosensors for the instant detection of bacterial and viral pathogens
  • Influenza A, H1N1 (swine flu), H5N1 (avian flu), Strep A, stomatitis, periimplantitis and periodontitis
  • Biosensor screening platform for high-throughput for identification of new biosensor targets for new biosensor products

Development partially funded by grants from the German Federal Ministry of Education and Research (BMBF)

Lead Products:

COVID-19 rapid PCR Kit

  • Diagnostic level accuracy, rapid results (<25 minutes), minimal lab equipment
  • European commercial approval and product launch planned for Q1 2021

Periimplantitis oral biosensor

  • For the early detection of infection associated with dental implants
  • Biosensor releases an extremely bitter compound when exposed to the causative pathogenic bacteria
  • European commercial approval and product launch planned for Q4 2021 

3. XPhyto Laboratories Inc. & Vektor Pharma TF GmbH – Psychedelics

100% owned XPhyto subsidiaries

Exclusive agreements with leading German and Canadian universities

Germany:

  • Development of psychedelic drug formulations – sublingual and transdermal
  • Development of biotechnology process for industrial scale production of psilocybin API
  • 12-month development program commenced Q3 2020

Canada:

  • Certified analytical testing for cannabis and psychedelics
  • Development programs for industrial scale and EU GMP production of mescaline, MDMA, DMT, and cannabinoid isolates
  • Novel psychedelic drug formulations

Clinical validation planned for Germany and Canada

Hub On AGORACOM / Corporate Profile

CLIENT FEATURE: Valeo Pharma $VPH.ca $VPHIF An Innovative Canadian Pharma Company With 9 Products Currently Marketed And 7 Products In Pipeline $HLS.ca $MDP.ca $GUD.ca $RX.ca

Posted by AGORACOM-JC at 1:56 PM on Thursday, December 31st, 2020

(VPH: CSE) (VPHIF: OTCQB) (VP2: FSE)

www.valeopharma.com

Why Valeo Pharma?

  • Commercial stage revenue generating Canadian pharmaceutical company
  • Approaching EBITDA positive in coming months
  • 9 products currently marketed ($40M. estimated peak sales / year)
  • 7 additional products in pipeline ($45M. estimated peak sales / year)
  • In-license business model, no development or clinical risk
  • $1.5M in quarterly revenue ending July 31, 2020
  • $5.26M in revenue for 9 months ending July 31, 2020

What Exactly Does Valeo Pharma Do?

  • Acquires Canadian rights to commercial stage, innovative and proprietary drugs
  • Commercializes innovative prescription products in Canada
  • Focused on Neurodegenerative Diseases,  Oncology and Hospital Specialty Products
  • Internally manages portfolio through all stages of commercialization

Watch Our Recent Interview:

Hub On AGORACOM / Corporate Profile

FULL DISCLOSURE: Valeo Pharma is an advertising client of AGORA Internet Relations Corp.

CLIENT FEATURE: Universal #PropTech $UPI.ca Delivering Healthy Building Solutions and Services For Building Developers, Owners and Operators #AI #IoT $SNE $MSFT $HON

Posted by AGORACOM-JC at 9:43 AM on Wednesday, December 23rd, 2020

UPI: TSX-V

www.universalproptech.com

As the name implies “PropTech” is a combination of two words and stands for “property technology.”  As simple as that is, the implementation and importance of PropTech is anything but. 

Like every other industry on the planet that is incorporating technology to create greater efficiencies and experiences, the commercial real estate market is no different and is seeing the rapid adoption of;

  • Artificial Intelligence
  • Machine learning
  • Big data
  • Internet of Things (IoT Sensors)
  • Cloud computing

To create cost savings by reducing and even eliminating existing costs, create greater efficiencies for the operation and maintenance of real estate assets, as well as, improve the design of new builds.

IMPACT OF COVID-19

The COVID-19 pandemic has served to significantly increased the demand for PropTech in the commercial real estate market as follows:

  • The need for solutions to get workers back into workplace buildings and offices. Specifically, the need to identify bacteria and viruses in indoor air quality, as well as, the ability to sanitize immediately and effectively.
  • The need to create even greater cost savings and efficiencies for real estate owners that will continue suffering losses until workers significantly return to the workplace.

WHY UNIVERSAL PROPTECH (UPI:TSXV)?

Whereas many companies are just now trying to capitalize on the opportunities presented in the current and massive future of PropTech, Universal PropTech Inc. (“UPI”) a diversified investment platform delivering healthy building solutions and services for building developers, owners and operators in Canada.  More than just lip service, UPI has been successfully delivering its PropTech solutions for years, with revenues over the last 3 years as follows:

2017 – $13.8M

2018 – $13.7M

2019 – $15.9M

Headquartered in Toronto, UPI has offices across Canada including Halifax,Montreal, and Ottawa. 

COMPANY HIGHLIGHTS

  • Used in Federal Government facilities for over 40 years
  • Provides real estate managers turnkey HVAC Building Controls design, equipment, installation and ongoing operations and maintenance services for Industrial, Commercial, Institutional and Multi-residential customers
  • Already possesses under-utilized IP in building controls to add in additional monitoring inputs and equipment controls
  • Diverse revenue streams via products, installations and ongoing
  • Key strategic partnerships afford the ability to monitor real-time utility meters, key BAS and systems data in a building.
  • Team has the capability to make sense of this data and apply advanced web tools to make recommendations to fine tune a building, saving from 5% to 15% of a facilities energy spend without capital expenditure
  • VCI offers the depth and breadth of Building Automation Systems (BAS) knowledge and products from the likes of Siemens and Honeywell to support building automation systems

RECENT NEWS

COVID-19 STRATEGY

As businesses return to the office, property managers must think about the design and safety of their buildings for occupants. Traditional cleaning methods are ineffective at preventing transmission. UV technology is able to sanitize all surfaces free from pathogens. UPI is capitalizing on this opportunity by building and acquiring UV technology as it is the best in the market to administer and integrate it into healthy buildings in Canada.

FIND OUT MORE:

Hub On AGORACOM / Corporate Profile

CLIENT FEATURE: Innocan Pharma $INNO.ca Developing The Pharmaceutical Guided Missile To Defeat Coronavirus Lung Infections $CGC.ca TLRY $VFF.ca $APHA $OVAT.ca $KHRN.ca

Posted by AGORACOM-JC at 11:38 AM on Tuesday, December 15th, 2020
Innocan-Blog

Innocan Pharma Corporation (INNO: CSE) (IP4:FSE) is developing the pharmaceutical guided missile to defeat coronavirus lung infections. The company specializes in the development of new drug platforms which combine unique properties of Cannabinoids. 

3 Fully Operating Divisions For Investor Diversification

Innocan has 3 fully operating divisions to address the market for Cannabis products.  As a Cannabis investor, why limit yourself to a Company with just one specialty, when Innocan offers you exposure to both the exploding world of cannabis pharma, as well as, a portfolio of patent-pending and launch ready consumer health products.

PHARMACEUTICAL – THE GUIDED MISSILE – Revolutionary technology targeting lungs infected with coronavirus or other viral infections.

CONSUMER RETAIL – DERMA COSMETICS – A premium derma cosmetics brand, manufacturing has commenced with distribution agreements in place.

OVER THE COUNTER (OTC) PRODUCTS FOR PAIN RELIEF – patent-pending CBD pain relief brand received FDA technical validation.

Global Manufacturing / Distribution Agreements

  • Endless Sky Inc. a Canadian large scale Cannabis extractor (Manufacturing and Distribution – Canada)
  • Swiss CBD provider Cloud 9 Switzerland LLC (Distribution – Italy and Switzerland)
  • Active Therapeutics Ltd of Lancashire, United Kingdom (Distribution – UK and Ireland markets)
  • iAmHealth Distribution UG (Distribution – Germany)

Completed Trademark Registration in the EU, UK and Switzerland

  • Completion of the registration of its trademarks: Innocan Pharma, Relief & Go and SHIR in the EU, UK and Switzerland.
  • These trademarks represent Innocan’s OTC and derma cosmetic brand products that were recently launched in the German and UK markets.

Superior Management Team

In the small cap world, the jockey(s) that drive the horse are just as important as the horse itself.  The InnoCan Leadership Group Is Incomparable In The Small Cap World, Comprised Of Leading Israeli Pharmaceutical Executives including:

  • Executive Chairman (Ron Mayron) was the CEO Of Teva Israel, one of the largest generic pharmaceutical companies in the world
  • Co-Founder & VP Business Development (Yoram Drucker) was the Founder of 2 NASDAQ Companies (Pluristem & Brainstorm)
  • Chief Technology Officer (Nir Avram) is a former member of the pharma innovation team at Perrigo, producer of OTC consumer goods and specialty pharma.
  • Chief Executive Officer (Iris Bincovich) has a proven track record in opening global markets, having managed hundreds of successful transactions in OTC, cosmetics and dermatology.

Together they have built one of the most formidable teams in the small cap cannabis world

Hub On AGORACOM / Corporate Profile